Missing a Spravato Dose During Induction Phase
Yes, a patient can miss a dose of Spravato during the induction phase and still complete induction, provided there is no worsening of depressive symptoms—simply continue with the current twice-weekly dosing schedule. 1
FDA-Approved Guidance on Missed Doses
The FDA label explicitly addresses this scenario with clear instructions: "If a patient misses treatment session(s), provided there is no worsening of their depressive symptoms, the patient should continue the current dosing schedule." 1 This guidance applies to both induction and maintenance phases, though the label specifically notes that dose schedule adjustments (reverting to more frequent dosing) are primarily relevant during maintenance treatment when depression symptoms worsen. 1
Induction Phase Structure
The standard induction phase consists of:
- Twice-weekly dosing for 4 weeks (56 mg or 84 mg per session)
- Target of 8 total treatment sessions
- Therapeutic benefit should be evaluated at the end of induction to determine continuation 1
Real-World Implementation Considerations
Important caveat: Real-world data reveals that patients typically require significantly more time than the label-recommended 28 days to complete induction. A 2024 study found the mean time to complete 8 esketamine sessions was 73.2 days (versus the expected 28 days), with 75.2% of patients going on to complete maintenance treatment. 2 This suggests clinical flexibility in timing is both common and acceptable in practice.
Clinical Decision Algorithm for Missed Doses
If dose(s) missed during induction:
Assess depression status:
- No worsening → Continue twice-weekly schedule, extend induction timeline as needed
- Worsening symptoms → Evaluate whether to continue esketamine or consider alternative interventions
Monitor for therapeutic benefit at completion:
- The critical endpoint is completing adequate treatment sessions (typically 8), not rigid adherence to a 4-week timeline
- Evidence of benefit should be assessed before transitioning to maintenance 1
Safety and Efficacy Context
Long-term studies demonstrate that patients who complete induction (even with extended timelines) show sustained improvement, with mean MADRS score reductions of -16.4 points maintained through maintenance phases. 3, 4 The key is achieving adequate exposure to treatment sessions rather than strict calendar adherence.
Bottom line: Missing doses during induction does not disqualify completion of the phase—the focus should be on achieving the target number of treatment sessions while monitoring clinical response, not rigid calendar compliance.